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ABSTRACT
Background. There are no good data in the literature on the prevalence of inflammatory bowel disease (IBD) in patients with
kidney disease and we do not know whether IBD affects the course of kidney disease or if the type of IBD is an influential
factor. The aim of this study was to evaluate the prevalence of IBD among patients who have undergone renal biopsies due
to clinical indications and to elucidate whether the presence of IBD influences renal and patient outcomes.
Methods. We collected retrospective data on concomitant diseases, especially IBD, from adult patients undergoing renal biopsy
for any clinical indication between 2000 and 2012 at Tampere University Hospital, Tampere, Finland. Information was
systematically collected on the activity of IBD, medication for IBD, surgery performed for IBD and markers of kidney function.
Results. Of the 819 patients biopsied, 35 (4.3%) had IBD. The prevalence of IBD was 13.3 and 4.6% in patients with
tubulointerstitial nephritis (TIN) and immunoglobulin A nephropathy (IgAN), respectively. In comparison, the prevalence of
IBD in the Finnish population is 0.6%. Ulcerative colitis and Crohn’s disease were equally represented. The presence of IBD
showed no impact on renal and patient outcomes.
Conclusions. IBD should not be overlooked in patients undergoing renal biopsies, especially those diagnosed with TIN or
IgAN. The renal findings did not associate with the activity of intestinal inflammation. Whether a concomitant IBD truly
affects the course of chronic kidney disease should be examined in further studies.
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INTRODUCTION
Many publications have raised our awareness of the relation-
ship between kidney diseases and increased intestinal perme-
ability. Chronic kidney disease (CKD), and especially uraemia,
alters the intestinal barrier and microbiome. The loss of the
ability to prevent the influx of microbial toxins and other harm-
ful products leads to local and systemic inflammation, which
can further promote deterioration in kidney function [1–3]. This
phenomenon probably promotes cardiovascular diseases as
well, which are one of the leading causes of death in patients
with end-stage renal disease (ESRD) [4]. Interestingly, intestinal
permeability seems to be already increased in the earlier stages
of CKD [5]. The linkage between the most common primary glo-
merulopathy [6], immunoglobulin A nephropathy (IgAN) and
the mucosa is well known [7, 8]. Genome-wide association stud-
ies (GWASs) in patients with IgAN have identified risk loci in
the genes involved in intestinal mucosa integrity and the im-
mune network [9]. In one recent study, patients with IgAN who
had persistent proteinuria were treated with targeted-release
enteric budesonide, which resulted in a significant reduction in
proteinuria [10].
Inflammatory bowel diseases (IBDs), including ulcerative co-
litis (UC) and Crohn’s disease (CD), are increasingly common
chronic inflammatory disorders of the gastrointestinal tract: the
prevalence of IBD is currently 0.2–0.7% in Western countries
[11–14]. Inflammation affects the large intestine and rectum in
UC [15], whereas inflammation and progressive bowel damage
can be present in any part of the intestine in CD [16]. A third en-
tity is unclassified IBD (IBDU), in which inflammation of the in-
testine with chronic colitis is present but no characteristic
histological signs of UC or CD are found [11]. IBD requires life-
long management. Renal damage in patients using 5-aminosali-
cylic acid (5-ASA) medication is a rare but well-documented
complication [17–20]. IBD is not restricted to the gastrointestinal
tract; 6–47% of sufferers also experience extraintestinal mani-
festations (EIMs) [21, 22]. The organs most commonly affected
include the skin, eyes, joints and biliary tract [21]. The preva-
lence of renal or urinary manifestations can be as high as 20%,
and they are largely explained by urological complications such
as nephrolithiasis [23, 24]. Renal diseases in conjunction with IBD
have been the subjects of primarily case reports [25, 26], and only
a few register-based case series have been published [27, 28].
The aims of this study were to evaluate the prevalence of
IBD among patients who have undergone renal biopsies due to
clinical indications and to elucidate whether the presence of
IBD has an influence on renal and patient outcomes.
MATERIALS ANDMETHODS
Patients and study design
The study cohort comprised 824 consecutive patients >16 years
of age who had undergone a renal biopsy due to clinical indica-
tions at the Division of Nephrology at Tampere University
Hospital (TAUH), Tampere, Finland, between January 2000 and
December 2012. The data were missing in five patients, giving
the study population of 819 patients. All patients included in
the study provided written informed consent. If the same pa-
tient was biopsied twice during the study period, then the first
diagnostic biopsy was included in the study. Renal biopsy speci-
mens were taken and processed using standard methods as de-
scribed earlier [29]. All specimens were studied with light and
immunofluorescence microscopy by two renal pathologists.
The indications for renal biopsies were classified into three
groups: (i) abnormal urinary finding, including focal nephritic
syndrome (haematuria and daily urinary protein excretion
<1.5 g), diffuse nephritic syndrome (haematuria and daily uri-
nary protein excretion >1.5 g), nephrotic syndrome (daily uri-
nary protein excretion >3.5 g without haematuria), proteinuria
(daily urinary protein excretion 0.3–3.5 g without haematuria)
and haematuria (daily urinary protein excretion <0.3 g); (ii) renal
insufficiency (elevated creatinine level) and (iii) any other indi-
cation. Based on the histopathological findings of the renal bi-
opsy specimens, five groups were categorized: glomerular
diseases, tubulointerstitial diseases, vascular diseases, other
findings (e.g. cystic and congenital diseases) and no glomeruli
(inadequate sample) [30]. Patients were divided into two groups
based on whether they were diagnosed with IBD or not.
Clinical data on kidney disease
The histories of all 819 patients were retrospectively collected
from the medical records of TAUH between 2014 and 2016 [8].
Plasma creatinine concentration, quantitative 24-h urinary pro-
tein excretion and haematuria data were gathered from medical
records at the time of the renal biopsy and the most recent
follow-up. The urine dipstick test for haematuria was dichoto-
mized as negative (values 0 or þ) or positive (þþ or þþþ).
Estimated glomerular filtration rate (eGFR) was defined using the
Chronic Kidney Disease Epidemiology Collaboration equation
[30]. The annual change in eGFR was calculated by dividing the
difference between the final and baseline values of eGFR by the
number of years of follow-up. Only patients followed up for >1
year after the renal biopsy with preserved kidney function (no
transplantation or chronic dialysis started during follow-up)
were included in the calculations of kidney function at the most
recent follow-up. Furthermore, data on chronic dialysis treat-
ment or renal transplantation during follow-up were recorded
and collectively called ESRD. The follow-up for individual
patients was concluded at the last office visit or the last reliable
set of laboratory results, whichever was closer to the time of data
collection.
Clinical data on IBD
Information regarding other diagnosed diseases, including IBD,
was collected systematically. The EIMs comprised diseases of
organs commonly accepted to be involved in IBD—diseases of
the joints, eyes, skin, liver, biliary tract and urinary tract—as well
as thrombotic events. Detailed data on IBD activity, medication,
location, surgery and EIMs were collected. The immunomodula-
tory medications for IBD included azathioprine, methotrexate,
glucocorticoids or tumour necrosis factor (TNF) inhibitors. IBD
flare-up was defined as the need for systemic glucocorticoid
medication equivalent to 30 mg of prednisolone. The site of IBD
was determined by means of endoscopy or gastrointestinal im-
aging (e.g. enteric magnetic resonance imaging) reports and
grouped into five different categories as follows: proctitis, left-
sided colitis (including proctosigmoiditis), pancolitis/ileocolonic,
small intestinal (no colonic affliction) and unknown. Abdominal
surgery denoted any surgical procedure to the intestine (includ-
ing appendectomy); operations on abdominal fistulas, strictures,
hernias or abscesses and cholecystectomy.
Statistical methods
The data are presented as medians and ranges for continuous
variables and numbers and percentages for categorical
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variables. Groups were compared using the chi-square test,
Fisher’s exact test, independent t-test or Mann–Whitney U-test,
as appropriate. Survival (ESRD as event) was determined using
Kaplan–Meier curves and differences between IBD (yes/no) were
compared by log-rank test. Univariate and multivariable analy-
ses (adjusted for age, gender and presence of IBD) were per-
formed using Cox proportional hazards regression. Hazard
ratios and their 95% confidence intervals are given. All tests
were two-sided and P < 0.05 was considered statistically signifi-
cant. All statistical testing was performed using SPSS version
25.0 (IBM, Armonk, NY, USA).
Ethical consideration
The study protocol was approved by the Ethics Committee of
Tampere University Hospital. All subjects gave written informed
consent at the time of the renal biopsy.
RESULTS
Patient characteristics, renal biopsy findings and the
prevalence of IBD
Twenty-eight (3.4%) of 819 patients had IBD at the time of renal
biopsy and an additional 7 patients were diagnosed with IBD dur-
ing the follow-up. Therefore a total of 35 (4.3%) patients had IBD
(Table 1). The patients with IBD were younger than the patients
without IBD. There were no differences in indications for renal bi-
opsy between the patients with and without IBD (Table 1).
The most common renal biopsy finding in the patients with
IBD was acute (four patients) or chronic (four patients) tubuloin-
terstitial nephritis (TIN). Altogether, 22.9% of the patients with
IBD presented with TIN, while 7 patients (20.0%) had IgAN. Ten
patients had glomerular diseases other than IgAN, two patients
had tubulointerstitial diseases other than TIN and eight
patients had findings categorized as vascular diseases or other
renal findings (Table 2). Tubulointerstitial diseases were more
often found in the patients with IBD when compared with
patients without IBD (28.6 versus 12.5%; P¼ 0.017) and glomeru-
lar diseases dominated in the patients without IBD when
compared with patients with IBD (70.9 versus 48.6%; P¼ 0.007).
Among the patients without IBD, TIN was diagnosed in 6.7%
and IgAN in 18.4% of patients. Overall, the prevalence of IBD in
the patients with TIN was 13.3%. Seven of 151 patients (4.6%)
with IgAN had IBD compared with 8 of 308 patients (2.6%) with a
glomerular disease other than IgAN (P¼ 0.164).
Patients with IBD and TIN were almost exclusively women
(seven of eight patients), while no sex difference was found in
patients with TIN and with no IBD (female 50.0%). Patients with
a glomerular disease (including IgAN) and IBD were predomi-
nantly male [14/17 patients (82.4%)]. A preponderance of males
was also found in patients with glomerular disease and no IBD
[344/556 patients (61.9%)].
Table 1. Basic characteristics of patients undergoing renal biopsy, indications for renal biopsies and renal biopsy findings
Patients with IBD
(n¼35)
Patients without
IBD (n¼ 784)
P-value
n % n %
Male 20 57.1 491 62.6 0.593
Age, median (range), years 49 (18–76) 59 (16–85) 0.026
Weight, median (range), kga 71 (46–112) 81 (23–150) 0.022
Height, median (range), cmb 172 (160–187) 173 (120–198)
Indications for renal biopsies 0.285
Abnormal urinary findingc 22 62.9 586 74.7
Renal insufficiency 12 34.3 185 23.6
Other causes 1 2.9 13 1.7
Renal biopsy findings 0.026
Glomerular diseases 17 48.6 556 70.9
Tubulointerstitial diseases 10 28.6 98 12.5
Vascular diseases 1 2.9 18 2.3
Other findings 7 20.0 98 12.5
Inadequate sample 0 0 14 1.8
Previous kidney transplantation 2 5.7 56 7.1 0.747
Number of subjects available: a453, b639. cFocal nephritic syndrome, diffuse nephritic syndrome, nephrotic syndrome, proteinuria, haematuria.
Table 2. Renal biopsy findings in 35 patients with IBD
Diagnosis n
Glomerular diseases
IgA GN 7
Membranous GN 2
IgM GN 2
Extracapillary GN 1
Mesangial, proliferative GN 1
Mesangial, sclerosing GN 1
Focal segmental glomerulosclerosis 1
Glomerulosclerosis, NOS 1
Amyloid nephropathy 1
Tubulointerstitial diseases
Acute TIN 4
Chronic TIN 4
Myeloma cast nephropathy 1
Acute tubular necrosis 1
Vascular diseases
Arteriosclerosis (hyalinic) 1
Other findings
Normal finding 3
Morphologic description only 2
Chronic cellular graft rejection 2
NOS, not otherwise specified.
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Renal outcomes
The median follow-up time was 59 months in patients with IBD
and 66 months in patients without IBD. There was no difference
between the groups in eGFR at the time of renal biopsy or at the
most recent follow-up. Patients with IBD had significantly lesser
amounts of proteinuria at the time of renal biopsy (Table 3). The
24-h urinary protein excretion was quantitated in 26 of 35
patients with IBD. Of these, nine (34.6%) were using immuno-
modulatory medication at the time of renal biopsy. Yet the
amount of proteinuria did not differ between those who were
on immunomodulatory medication and those who were not
(median of the 24-h excretion 0.8 and 0.9 g, respectively;
P¼ 0.833). Two patients with IBD (5.7%) and 142 patients without
IBD (18.1%) progressed to ESRD (P¼ 0.068). In Figure 1, a Kaplan–
Meier curve shows the difference between patients with and
without IBD and the occurrence of ESRD. We also performed
Cox logistic regression analysis to determine the risk factors for
ESRD (Table 4). Male gender was found to be a strong and inde-
pendent predictor of ESRD, but the presence of IBD did not asso-
ciate with the risk for ESRD.
Phenotypes of IBD
Altogether, there were 14 cases of CD, 14 cases of UC and 7 cases
of IBDU. Neither CD nor UC seemed to dominate in the different
renal findings for TIN (three CD, four UC and one IBDU), IgAN
(four CD and three UC) or other GD (four CD, four UC and two
IBDU). All patients with TIN had a previous diagnosis of IBD and
all of them used or had prior use of 5-ASA medication at the
time of renal biopsy. Similarly, patients with glomerular dis-
eases who had a diagnosis of IBD at the time of renal biopsy (13
patients) all had a history of 5-ASA medication. Altogether,
37.1% of the patients with IBD were taking either steroid or
other immunomodulatory medication (azathioprine, metho-
trexate or TNF inhibitor) at the time of the renal biopsy. In terms
of inflammatory activity, one-quarter (7/28) of the patients with
previous IBD had a flare-up of IBD during the year preceding the
renal biopsy.
Diffuse intestinal inflammation (pancolitis or ileocolonic)
was the most common (54.2%) location of IBD, irrespective of
the renal finding. Nine of 35 (25.7%) patients had undergone ab-
dominal surgery. Most of the patients with IgAN and IBD had an
EIM (71.4%), while just 12.5% of the patients with TIN and 20.0%
of the patients with other glomerular diseases had an EIM.
DISCUSSION
This study showed the prevalence of IBD among people under-
going renal biopsy to be as high as 3.4%; during the follow-up,
the prevalence of diagnosed IBD was further elevated to 4.3%.
As the pathogenesis of diseases can presumably take a variable
number of years before clinical symptoms arise and the spec-
trum of symptoms of both renal diseases and IBD is wide, a
clear determination cannot be made as to whether renal disease
or IBD preceded the other in individual patients.
The prevalence of IBD in our study was large compared with
that found (0.2%) in a previous study by Ambruzs et al. [27]. The
major difference in the prevalence of IBD in these two studies is
most likely explained by differences in study designs. Between
1986 and 2008, the prevalence of IBD has increased from 0.2 to
0.6% in Finland [11, 12]. There are few published prevalence
Table 3. Renal function at the time of renal biopsy and at the latest follow-up
Patients with IBD (n¼ 35), Patients without IBD (n¼ 784), P-value
median (range) median (range)
At renal biopsy
Plasma creatinine (lmol/L) 133 (56–671) 123 (17–1776) 0.921
eGFRa (mL/min/1.73 m2) 44 (6–130) 51 (2–172) 0.711
24-h urinary protein excretion (g/day)b 0.8 (0.1–6.4) 1.5 (0.1–24.2) 0.040
Haematuria, n (%)c 12 (37.5) 346 (46.9) 0.366
At the latest follow-up
Duration of follow-up (months) 59 (0–178) 66 (0–183) 0.619
Plasma creatinine (lmol/L)d,e 90 (49–276) 104 (11–1013) 0.137
eGFR (mL/min/1.73 m2)d,e 78 (19–117) 57 (4–197) 0.118
Annual change of eGFR (mL/min/1.73 m2/year)d,f 0 (11–35) –1 (84–70) 0.086
aeGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation. Number of subjects available:
b621;
c769;
dexcluded if treated with dialysis, had received renal transplantation during the follow-up or the follow-up had lasted <12 months;
e567;
f552.
FIGURE 1: Kaplan–Meier survival curves for 35 patients with IBD and 783
patients with no IBD for progression to ESRD (log-rank P¼0.086).
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rates of IBD globally, but they seem to vary from 0.2 to 0.7% [11,
13, 14]. Thus the prevalence of IBD in the present cohort of
patients who had a clinical indication for the renal biopsy was
approximately 7-fold compared with that in the general
population.
The prevalences of IBD in patients with TIN and IgAN were as
high as 13.3 and 4.6%, respectively. This is about 20- and 8-fold
the IBD prevalence in the general population, respectively. In pre-
vious studies, the prevalence of IBD in IgAN patients has varied
from 0.7 to 1.6% [27, 31, 32]. To our knowledge, the prevalence of
IBD in patients with TIN has not been published before. There is
no way to differentiate patients in this cohort for whom TIN was
related to 5-ASA medication, as all the patients with TIN had an
ongoing or previous history of 5-ASA use. Thus the high preva-
lence of IBD in patients with TIN might have been related to 5-
ASA medication even though the correlation of 5-ASA to TIN has
remained controversial in the literature [18, 20, 33]. In general,
patients without IBD had greater amounts of proteinuria at the
time of renal biopsy, a finding that most likely is explained by
the dominance of glomerular diseases in patients without IBD.
The preponderance of the female gender in patients with IBD
and TIN was noteworthy, but the small number of patients with
both IBD and TIN might have influenced the results. The finding
of a male majority in patients with glomerulonephritis (GN) in
general has been noted in earlier publications [34, 35] and re-
cently in patients with IBD and GN as well [28]. Patient cases of
TIN and IBD have not shown female dominance [33, 36, 37].
The connection between IgAN and intestinal inflammation
is clearly recognized [7]. The HLA-DR1 allele for IgAN and the
HLA-DR1/DQw5 allele for CD have led to a theory of a common
genetic basis for both diseases [24]. GWASs in patients with
IgAN have identified risk loci in genes involved in intestinal mu-
cosal integrity and the immune network. Some of the risk
alleles for IgAN are also associated with the risk for IBD [9]. The
number of inflammatory cells in the intestinal mucosa in-
creased in patients with GN [38–40]. However, no previous publi-
cation has shown such a high prevalence of IBD in patients with
IgAN.
Previously, more than half of the patients with IgAN have
presented with various other parallel diseases [31, 32]. No pub-
lished data exist on the incidence of IBD and IgAN in association
with a third disease entity, but patient cases of such triads have
been published [41–43], as has one recent case series [28]. In our
cohort, 71% of patients with IBD and IgAN had another EIM.
Male gender presented as a risk factor for ESRD. This finding
is in line with previous publications [44, 45]. IBD was not related
to an elevated risk for ESRD. The impression that the activity of
IBD affects renal disease can arise when reading published pa-
tient cases [46–48]. Defining the activity of the disease in a retro-
spective manner is rather inaccurate. We can assume, based on
the data shown, that the patients in the present study did not
represent particularly difficult cases of colitis. Fewer than half
of the patients with a previous diagnosis of IBD either had a
flare-up during the preceding year before the kidney biopsy or
were on an immunomodulatory medication at the time of the
renal biopsy. Nevertheless, more than half had no clinical sign
of active intestinal inflammation, and when the total popula-
tion of 35 patients with IBD was evaluated, about one-third of
the patients with IBD had intestinal inflammatory activity at
the time of the renal biopsy. A quarter of the patients with IBD
had undergone abdominal surgery at any given time point, ei-
ther before or after the kidney biopsy. No clear difference was
noticed in the concomitance of renal disease and IBD, as CD and
UC were equally represented. In a recent letter published by
Hungarian researchers, the few cases of GN found in patients
with IBD were more often in conjunction with CD [28].
The renal biopsies in this study were taken at one centre and
analysed by two renal pathologists. The unifying indications for
renal biopsies as well as the interpretation of the renal samples
are the strengths in the present study. Patients with renal dis-
eases in our university hospital district are mostly followed up
and treated in the nephrology unit of the university hospital. In
a similar way, most of the patients with active IBD are followed-
up by the university hospital. Thus we have been able to collect
real-life data with long follow-up times. Due to the retrospective
nature of the study, some of the information collected may be
inaccurate or insufficient. Another obvious limitation is that
some of the patients with no diagnosed IBD might have had
clinically silent IBD, but the number of such patients presum-
ably would be low and would not affect the results of the study.
To conclude, our study showed a remarkable prevalence of
IBD in patients undergoing renal biopsy for any clinical indica-
tion. IBD should be kept in mind when the renal biopsy finding is
either TIN or IgAN. A lack of obvious gastrointestinal symptoms
does not necessarily indicate the absence of IBD, as more than
half of the patients biopsied were asymptomatic at the time of bi-
opsy. We do not yet know whether the coexistence of IBD and
CKD results in one influencing the other. This cohort was too
small to show either the benefit or disadvantage of IBD for CKD
even though patients with IBD did well when compared with
patients without IBD. Thus further studies are needed to exam-
ine the significance of concomitant IBD in patients with CKD.
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